Market LIVE
Published markets; coverage varies by country
Product profile · United States

TUKYSA

 ·  Patent Litigation & Settlement History ↓

IngredientTUCATINIB
Application typeNDA
Application213411
Product001
Dosage formTABLET
RouteORAL
Strength50MG
Approval date2020-04-17
Marketing statusPrescription
Status event—
ApplicantSEAGEN
Product source

Current GenericRadar decision

Year2034
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeTRUE_DS_PATENT
Anchor date2034-04-17
Patent anchor2034-04-17
Exclusivity anchor—
Protection date2038-04-27
First Final ANDA—
Status event—

US8648087 c28 tucatinib. TD2031-01-14 followed by PTE1189days; CRC combination tail2038-04-27.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
96939892027-05-09DP/U U-2788NYU
| B1C03P7 issued-claim review2026-10-15: U
———
96939892027-05-09ORANGE_BOOK U-2788NYU
English description not available.
———
94570932032-10-12DP/U U-2788NNDP
| B1C03P7 issued-claim review2026-10-15: DP
———
94570932032-10-12ORANGE_BOOK U-2788NNDP
English description not available.
———
115043702033-03-25U U-2788NNU
| B1C03P7 issued-claim review2026-10-15: U
———
115043702033-03-25ORANGE_BOOK U-2788NNU
English description not available.
———
86480872034-04-17DS/DP —YNTRUE_DS
| B1C03P7 issued-claim review2026-10-15: TRUE_DS
———
86480872034-04-17ORANGE_BOOK —YNTRUE_DS
English description not available.
———
112073242038-04-27U U-3783NNU
| B1C03P7 issued-claim review2026-10-15: U
———
112073242038-04-27ORANGE_BOOK U-3783NNU
English description not available.
———
116665722038-04-27U U-3783NNU
| B1C03P7 issued-claim review2026-10-15: U
———
116665722038-04-27ORANGE_BOOK U-3783NNU
English description not available.
———
120486982038-04-27U U-3783NNU
| B1C03P7 issued-claim review2026-10-15: U
———
120486982038-04-27ORANGE_BOOK U-3783NNU
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE2020-04-172025-04-17English description not available.YY2025-04-17
NCE
Full coverage date: 2025-04-17
Source
I-9062023-01-192026-01-19English description not available.NN——Source
I-9062023-01-192026-01-19English description not available.NN—
NCE
Full coverage date: —
Source
ODE-3092020-04-172027-04-17English description not available.NN——Source
ODE-3092020-04-172027-04-17English description not available.NN—
NCE
Full coverage date: —
Source
ODE-4222023-01-192030-01-19English description not available.NN——Source
ODE-4222023-01-192030-01-19English description not available.NN—
NCE
Full coverage date: —
Source

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (1)
TypeDateRoleBasisSource
ANNUAL_DECISION_RECHECK—ANCHOR_AND_TAILUS8648087 c28 tucatinib. TD2031-01-14 followed by PTE1189days; CRC combination tail2038-04-27.Source
Decision history
CurrentYearStatusReviewAnchorJudged
Y2034DEEP_REVIEWFINAL2034-04-172026-10-17 20:32:21
N2034DEEP_REVIEWFINAL2034-04-172026-10-15 00:56:39
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.